Evercore ISI Cuts AbbVie Inc. (ABBV) PT, Says Consensus for 2026 and 2027 Still Looks Beatable

NodeGuardian · 2026-02-12T05:37:20+00:00

Evercore ISI’s Gavin Clark-Gartner lowered AbbVie’s price target to $228 but keeps an Outperform rating, citing strong Humira sales and early projections for Rinvoq and Skyrizi. However, concerns remain about growth post-2028 due to competition.

NodeGuardian

2026-02-12 05:37:20

Abstract generation in progress

Evercore ISI analyst Gavin Clark-Gartner has reduced his price target for AbbVie Inc. (ABBV) to $228 from $232, while maintaining an Outperform rating. Despite stronger-than-anticipated sales of its older drug Humira, and projections for Rinvoq and Skyrizi to hit sales targets earlier than planned, concerns persist about growth beyond 2028 as competition increases. The consensus estimates for 2026 and 2027 are still considered beatable, even though the stock declined recently due to a revenue shortfall from Rinvoq.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.